Search results for "GLUCAGON-LIKE"

showing 10 items of 110 documents

Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins

2019

Incretins are metabolic hormones released after a meal that increase insulin secretion from pancreatic β-cells. The two main incretins are the intestinal peptides glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Both induce a decrease in glycemia, slow down the absorption of nutrients, and are inactivated by the enzyme dipeptidyl peptidase-4. Recently, incretin-based therapies have become a useful tool to treat diabetic patients, and different studies have focused on the identification of glucagon-like peptide-1 receptor agonists, including those of natural origin. This review focuses on the new findings of medicinal plants and natural products as possible active ag…

Enfermedad cardiovascularPharmaceutical SciencePharmacology01 natural sciencesAnalytical Chemistry//purl.org/becyt/ford/1 [https]Tratamiento médicoDPP-4Drug DiscoveryReceptorchemistry.chemical_classificationGIPGLUCAGON-LIKE PEPTIDE-1digestive oral and skin physiologyGlucagon-like peptide-1Diabetes mellitus tipo 2HomeopatíaINCRETINSMolecular MedicineCIENCIAS NATURALES Y EXACTAShormones hormone substitutes and hormone antagonistsendocrine systemOtras Ciencias BiológicasIncretinIncretinsCiencias BiológicasDiabetes mellitusDiabetes MellitusmedicineAnimalsHumansHypoglycemic Agents//purl.org/becyt/ford/1.6 [https]Dipeptidyl peptidase-4PharmacologyBiological ProductsPlants MedicinalGuar gum010405 organic chemistryOrganic ChemistryGLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDEmedicine.diseaseDIPEPTIDYL PEPTIDASE-40104 chemical sciences010404 medicinal & biomolecular chemistryEnzymeComplementary and alternative medicinechemistryGLP-1PhytotherapyHormone
researchProduct

Peripheral Glucagon Like Peptide 2 Analogue Administration Reduces Food Intake in Lean and Diet-Induced Obese Mice

2011

Food intakemedicine.medical_specialtyHepatologybusiness.industryGastroenterologyGlucagon-like peptide-2PeripheralDiet induced obesityEndocrinologyInternal medicinemedicinebusinessGLP-2Diet-induced obeseGastroenterology
researchProduct

GLUCAGON-LIKE PEPTIDE-1 MODULATES EXCITATORY CHOLINERGIC NEUROTRANSMISSION OF MOUSE DUODENUM AND COLON

2009

The incretin Glucagon-like-peptide-1 (GLP-1) is produced by enterendocrine L cells of the small intestine. It delays gastric emptying and reduces intestinal transit by inhibiting vagal activity. To date, no evidences are available about a direct peripheral influence on gastrointestinal smooth muscle cells. The purpose of the present study was to investigate in vitro the effects of GLP-1 on the spontaneous and evoked mechanical activity of murine duodenum and colon, recording intraluminal pressure, index of the circular mechanical activity, and isometric tension, index of the longitudinal mechanical activity. In both intestinal segments GLP-1 (up to 1 μM) did not affect spontaneous mechanica…

GLUCAGON-LIKE PEPTIDE-1colonduodenumef
researchProduct

GLUCAGON-LIKE PEPTIDE-1: GASTROINTESTINAL MOTILITY AND FOOD INTAKE

2012

GLUCAGON-LIKEPEPTIDE-1GASTROINTESTINALSettore BIO/09 - Fisiologia
researchProduct

Gastric relaxation induced by glucagon-like peptide-2 and receptorial expression in fasted or high-fat diet fed mice.

2011

Gastric relaxationmedicine.medical_specialtyEndocrinologyglucagon-like peptide-2high-fat dietHepatologyChemistryInternal medicineGastroenterologymedicineRelaxation (physics)High fat dietGlucagon-like peptide-2
researchProduct

Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women

2022

We showed that twenty weeks of SuperJump activity, an innovative workout training performed on an elastic minitrampoline, reduced bone resorption and increased bone formation in eumenorrheic women acting on the key points of the regulation of bone metabolism. The present study analyzed whether the gastrointestinal hormones are involved in the mechanism of action and if it has an impact on glucose homeostasis. The control group was composed of twelve women, similar to the exercise group that performed SuperJump activity for twenty weeks. The analysis was performed on blood samples and investigated GLP-1, GIP, GLP-2, PYY, ghrelin, glucose, insulin, insulin resistance, β-cell function, and ins…

Glucagon-like peptide-1endocrine systemBiological mechanismsGeneral Immunology and MicrobiologyGlucose‐dependent insulinotropic polypeptidedigestive oral and skin physiologyPhysical healthbiological mechanisms; physical health; sports and exercise physiology; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptideGeneral Agricultural and Biological Scienceshormones hormone substitutes and hormone antagonistsGeneral Biochemistry Genetics and Molecular BiologySports and exercise physiology
researchProduct

Glucagon-like peptide-2 relaxes mouse gastric fundus in vitro.

2009

Glucagon-like peptide-2 gastric fundus
researchProduct

Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registr…

2022

Abstract Aims Type 2 diabetes (T2DM) in patients with coronavirus disease-19 (COVID-19) is associated with a worse prognosis. We separately investigated the associations between the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and dipeptidyl peptidase-4 inhibitors (DPP-4i), and the risk of COVID-19 hospitalization and death. Methods and results Patients with T2DM registered in the Swedish National Patient Registry and alive on 1 February 2020 were included. ‘Incident severe COVID-19’ was defined as the first hospitalization and/or death from COVID-19. A modified Poisson regression approach was applied to a 1:1 propensity sc…

HospitalizationDipeptidyl-Peptidase IV InhibitorsGlucoseDiabetes Mellitus Type 2Glucagon-Like Peptide 1COVID-19 Dipeptidyl peptidase-4 inhibitors (DPP-4i) Glucagon-like peptide-1 receptor agonists Hospitalization Mortality Sodium-glucose cotransporter 2 inhibitorsHumansCOVID-19Pharmacology (medical)RegistriesCardiology and Cardiovascular MedicineGlucagon-Like Peptide-1 Receptor
researchProduct

Novel GPR120 agonist TUG891 modulates fat taste perception and preference and activates tongue-brain-gut axis in mice

2020

GPR120 is implicated as a lipid receptor in the oro-sensory detection of dietary fatty acids. However, the effects of GPR120 activation on dietary fat intake or obesity are not clearly understood. We investigated to determine whether the binding of TUG891, a novel GPR120 agonist, to lingual GPR120 modulates fat preference in mice. We explored the effects of TUG891 on obesity-related hormones and conducted behavioral choice tests on mice to better understand the physiologic relevance of the action of TUG891. In cultured mouse and human taste bud cells (TBCs), TUG891 induced a rapid increase in Ca2+ by acting on GPR120. A long-chain dietary fatty acid, linoleic acid (LA), also recruited Ca2+ …

Male0301 basic medicineAgonistlinoleic acidmedicine.medical_specialtyTasteextracellular signal-regulated kinase 1/2obesitymedicine.drug_classLinoleic acidQD415-436030204 cardiovascular system & hematologyBiochemistryReceptors G-Protein-CoupledMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyTongueInternal medicinemedicineAnimalsHumansReceptorCells CulturedResearch ArticlesCholecystokininchemistry.chemical_classificationPhenylpropionatesBiphenyl CompoundsBrainTaste PerceptionFatty acidGPR120Cell BiologyTaste BudsGastrointestinal MicrobiomeMice Inbred C57BL030104 developmental biologyEndocrinologychemistryglucagon-like peptide-1Hormone
researchProduct

Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high fat diet

2016

Previous studies suggested that endogenous glucagon-like peptide 2 (GLP-2) is dispensable for the regulation of glucose homeostasis under normal conditions, while it can play a beneficial role in obesity conditions. The purpose of the present study was to investigate whether chronic treatment with Gly2-GLP-2, a stable analogue of GLP-2, can have an impact on glycaemic and lipid control in mice fed a high-fat diet (HFD), an animal model of human obesity and insulin resistance. HFD mice were treated once a day with Gly2-GLP-2 for 4 weeks. Body weight, food intake, fasting glucose, intraperitoneal glucose tolerance, insulin-induced glucose clearance, glucose-stimulated insulin secretion, β-cel…

Male0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDrug Evaluation PreclinicalMicrovesicular SteatosisCarbohydrate metabolismDiet High-FatSettore BIO/09 - FisiologiaRandom Allocation03 medical and health sciencesEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusGlucagon-Like Peptide 2medicineAnimalsGlucose homeostasisObesityPancreasPancreatic islets.Glucose Metabolism Disordersbusiness.industrydigestive oral and skin physiologyInsulin resistancemedicine.diseaseGlucagon-like peptide-2LipidsObesityMice Inbred C57BL030104 developmental biologyEndocrinologyLiverPeptidesbusinessGLP-2Dyslipidemia
researchProduct